Literature DB >> 22510398

Primary brain tumours in adults.

Damien Ricard1, Ahmed Idbaih, François Ducray, Marion Lahutte, Khê Hoang-Xuan, Jean-Yves Delattre.   

Abstract

Important advances have been made in the understanding and management of adult gliomas and primary CNS lymphomas--the two most common primary brain tumours. Progress in imaging has led to a better analysis of the nature and grade of these tumours. Findings from large phase 3 studies have yielded some standard treatments for gliomas, and have confirmed the prognostic value of specific molecular alterations. High-throughput methods that enable genome-wide analysis of tumours have improved the knowledge of tumour biology, which should lead to a better classification of gliomas and pave the way for so-called targeted therapy trials. Primary CNS lymphomas are a group of rare non-Hodgkin lymphomas. High-dose methotrexate-based regimens increase survival, but the standards of care and the place of whole-brain radiotherapy remain unclear, and are likely to depend on the age of the patient. The focus now is on the development of new polychemotherapy regimens to reduce or defer whole-brain radiotherapy and its delayed complications.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22510398     DOI: 10.1016/S0140-6736(11)61346-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  240 in total

1.  Probucol suppresses human glioma cell proliferation in vitro via ROS production and LKB1-AMPK activation.

Authors:  Yong-sheng Jiang; Jing-an Lei; Fang Feng; Qi-ming Liang; Fu-rong Wang
Journal:  Acta Pharmacol Sin       Date:  2014-11-17       Impact factor: 6.150

2.  Effect of CDKN2A/B rs4977756 polymorphism on glioma risk: a meta-analysis of 16 studies including 24077 participants.

Authors:  Xuchen Qi; Yingfeng Wan; Qitao Zhan; Shuxu Yang; Yirong Wang; Xiujun Cai
Journal:  Mamm Genome       Date:  2015-11-17       Impact factor: 2.957

Review 3.  Microirradiation techniques in radiobiological research.

Authors:  Guido A Drexler; Miguel J Ruiz-Gómez
Journal:  J Biosci       Date:  2015-09       Impact factor: 1.826

4.  Symptoms and medication management in the end of life phase of high-grade glioma patients.

Authors:  J A F Koekkoek; L Dirven; E M Sizoo; H R W Pasman; J J Heimans; T J Postma; L Deliens; R Grant; S McNamara; G Stockhammer; E Medicus; M J B Taphoorn; J C Reijneveld
Journal:  J Neurooncol       Date:  2014-08-24       Impact factor: 4.130

5.  Improved Differentiation of Low-Grade and High-Grade Gliomas and Detection of Tumor Proliferation Using APT Contrast Fitted from Z-Spectrum.

Authors:  Jiaxuan Zhang; Wenzhen Zhu; Rongwen Tain; Xiaohong Joe Zhou; Kejia Cai
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

6.  Assessment of the association between XRCC1 Arg399Gln polymorphism and glioma susceptibility.

Authors:  Weijie Zhu; Jie Yao; Yi Li; Bainan Xu
Journal:  Tumour Biol       Date:  2013-11-21

7.  Association of BCL2-938C>A genetic polymorphism with glioma risk in Chinese Han population.

Authors:  Wei Li; Chunfa Qian; Linxiong Wang; Hong Teng; Li Zhang
Journal:  Tumour Biol       Date:  2013-11-28

Review 8.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

9.  A functional polymorphism in XRCC1 is associated with glioma risk: evidence from a meta-analysis.

Authors:  Xiangtai Wei; Duo Chen; Tao Lv
Journal:  Mol Biol Rep       Date:  2012-10-25       Impact factor: 2.316

10.  Splicing factor SRSF1 promotes gliomagenesis via oncogenic splice-switching of MYO1B.

Authors:  Xuexia Zhou; Run Wang; Xuebing Li; Lin Yu; Dan Hua; Cuiyun Sun; Cuijuan Shi; Wenjun Luo; Chun Rao; Zhendong Jiang; Ying Feng; Qian Wang; Shizhu Yu
Journal:  J Clin Invest       Date:  2019-01-14       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.